Cited by 866Acute Myeloid Leukemia ResearchCancer Genomics and DiagnosticsMultiple and Secondary Primary Cancers

Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes

Open access
Coombs, Catherine C., Zehir, Ahmet, Devlin, Sean M., Kishtagari, Ashwin, Syed, Aijazuddin, Jonsson, Philip, Hyman, David M., Solit, David B. +7 more·2017·Cell stem cell

Abstract

Clonal hematopoiesis (CH), as evidenced by recurrent somatic mutations in leukemia-associated genes, commonly occurs among aging human hematopoietic stem cells. We analyzed deep-coverage, targeted, next-generation sequencing (NGS) data of paired tumor and blood samples from 8,810 individuals to assess the frequency and clinical relevance of CH in patients with non-hematologic malignancies. We identified CH in 25% of cancer patients, with 4.5% harboring presumptive leukemia driver mutations (CH-PD). CH was associated with increased age, prior radiation therapy, and tobacco use. PPM1D and TP53 mutations were associated with prior exposure to chemotherapy. CH and CH-PD led to an increased incidence of subsequent hematologic cancers, and CH-PD was associated with shorter patient survival. These data suggest that CH occurs in an age-dependent manner and that specific perturbations can enhance fitness of clonal hematopoietic stem cells, which can impact outcome through progression to hematologic malignancies and through cell-non-autonomous effects on solid tumor biology.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.stem.2017.07.010

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • D-2-hydroxyglutarate (D2HG) inhibits numerous demethylases, leading to changes in genomic and transcriptomic methylation profiles as well as gene expression and genome topology.

    “D-2-hydroxyglutarate (D2HG) is one such oncometabolite, which inhibits numerous demethylases, leading to changes in genomic and transcriptomic methylation profiles as well as gene expression and genome topology 32,90-92 .”
  • One study found that CHIP mutations were more prevalent in patients treated for solid cancers than in populations not selected for cancer.

    “One study of a patient population treated for solid cancers found that CHIP mutations were more prevalent in this group than in populations not selected for cancer 77.”

    From Clonal hematopoiesis in human aging and disease (2019) · cites this paper as [77]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., Arcila, M. E., Ladanyi, M., Tallman, M. S., Levine, R. L., & Berger, M. F.
Affiliations
Memorial Sloan Kettering Cancer Center (US)
Corresponding author
  • Levine, Ross L.
  • Berger, Michael F.
Venue
Cell stem cell
Publisher
Elsevier BV
Published
2017-09
Volume
21
Issue
3
Pages
374-382.e4
ISSN
  • 1875-9777 (ISSN-L)
  • 1934-5909
OpenAlex
W2745259295
Cited by
866
References
39
Citations by year
2026: 76 · 2025: 105 · 2024: 105 · 2023: 115 · 2022: 139 · 2021: 76 · 2020: 105 · 2019: 81 · 2018: 54 · 2017: 8
FWCI
52.27
Type
journal article
Language
en
Open access
Locations
  • Cell stem cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • NIH National Cancer Institute (P30 CA008748)
  • Conquer Cancer Foundation American Society of Clinical Oncology Young Investigator Award
  • Stand Up to Cancer Convergence Program
  • National Science Foundation (NSF/SU2C 2015-003)
Topics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Epidemiology › Multiple and Secondary Primary Cancers
Keywords
clonal hematopoiesis, PPM1D mutation, TP53 mutation, survival outcomes, radiotherapy, chemotherapy, tobacco use, aging, somatic mutations
MeSH terms
Aged, Clone Cells, Female, Hematopoiesis, Humans, Male, Middle Aged, Mutation, Risk Factors, Cohort Studies, Survival Analysis, Treatment Outcome, Hematologic Neoplasms, Genetic Association Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review